In a recent webinar organized by the Alliance for a Stronger FDA, a top policy and legislation official from the U.S. Food and Drug Administration (FDA) provided insight to the agency’s approach to regulating cannabidiol (CBD) and kratom in foods and dietary supplements.
In the past year, FDA has acknowledged the need to design a novel regulatory pathway for CBD products after an internal working group concluded that there are notable health concerns that exist around CBD consumption, especially long-term use. The agency expressed that it does not intend to pursue rulemaking allowing CBD in foods or supplements, but FDA would be willing to work with U.S. Congress on the matter of forging a new framework for CBD oversight.